Thermo Fisher Scientific Inc. $TMO Stock Purchased by Artemis Investment Management LLP

Artemis Investment Management LLP grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 105.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 84,793 shares of the medical research company’s stock after buying an additional 43,523 shares during the quarter. Artemis Investment Management LLP’s holdings in Thermo Fisher Scientific were worth $57,240,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Titleist Asset Management LLC grew its stake in Thermo Fisher Scientific by 34.3% in the third quarter. Titleist Asset Management LLC now owns 822 shares of the medical research company’s stock worth $555,000 after purchasing an additional 210 shares in the last quarter. Apella Capital LLC increased its position in Thermo Fisher Scientific by 12.6% in the third quarter. Apella Capital LLC now owns 1,429 shares of the medical research company’s stock worth $946,000 after buying an additional 160 shares during the period. Everhart Financial Group Inc. lifted its position in Thermo Fisher Scientific by 22.0% in the 3rd quarter. Everhart Financial Group Inc. now owns 2,348 shares of the medical research company’s stock valued at $1,585,000 after purchasing an additional 424 shares during the last quarter. Avidian Wealth Enterprises LLC raised its holdings in shares of Thermo Fisher Scientific by 25.1% during the third quarter. Avidian Wealth Enterprises LLC now owns 1,896 shares of the medical research company’s stock valued at $1,280,000 after buying an additional 380 shares during the last quarter. Finally, Valeo Financial Advisors LLC boosted its position in Thermo Fisher Scientific by 11.7% during the 3rd quarter. Valeo Financial Advisors LLC now owns 3,005 shares of the medical research company’s stock worth $2,029,000 after acquiring an additional 315 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $17.54 during trading hours on Thursday, reaching $644.52. The stock had a trading volume of 1,426,760 shares, compared to its average volume of 2,247,260. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business’s fifty day moving average is $624.23 and its two-hundred day moving average is $539.29. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $694.33. The company has a market cap of $238.31 billion, a price-to-earnings ratio of 34.67, a PEG ratio of 2.75 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TMO shares. UBS Group upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and upped their target price for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a research report on Wednesday. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Finally, Citigroup cut Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $635.55.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 73,768 shares of company stock valued at $44,122,820 in the last three months. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.